Opportunity and Collaboration
Healthcare-associated infections remain a significant clinical and economic burden, particularly among vulnerable patients exposed to broad-spectrum antibiotics.
Antibiotic treatment can disrupt the gut microbiome, reducing its natural protective functions and creating an environment where potentially pathogenic organisms can proliferate.
KeepBio is developing a microbiome-based approach designed to help rebuild a healthy gut microbiome and support its natural protective functions.
10M Patients exposed to broad-spectrum antibiotics annually
$45B Annual economic burden associated with HAIs
$3B Estimated ICU opportunity
$600M Estimated Leukemia opportunity
Focused entry. Broader platform potential.
Our initial development programs focused on patient populations where antibiotic exposure, microbiome disruption, and infection risk converge;
ICU/Critical Care Leukemia Recurrent UTIs HCT/Transplants Other High-Risk
Where KeepBio is focusing first
ICU Patients receiving broad-spectrum antibiotics present an opportunity to demonstrate microbiome restoration as a strategy for supporting the microbiome’s natural protective function.
CRITICAL CARE
HEMATOLOGY & ONCOLOGY
Patients undergoing intensive treatment for leukemia and other hematologic conditions frequently experience significant antibiotic exposure and microbiome disruption.
Partner with KeepBio to advance the science
KeepBio is seeking collaborations with hospitals, investigators, and clinical research organizations interested in studying microbiome restoration in vulnerable patient populations.
We welcome discussions about clinical studies, translational research, and real-world evidence generation in all patients with pathogen-dominated conditions.
PROTECTED INNOVATION
Building a defensible microbiome platform
KeepBio’s technology and development approach are protected through a combination of patents and proprietary trade secrets, creating intellectual property protection around key elements of the platform and its application.